25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Oragenics Inc
Buy, Hold or Sell?

Let's analyze Oragenics together

I guess you are interested in Oragenics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Oragenics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Oragenics Inc

I send you an email if I find something interesting about Oragenics Inc.

1. Quick Overview

1.1. Quick analysis of Oragenics (30 sec.)










1.2. What can you expect buying and holding a share of Oragenics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
27.5%

What is your share worth?

Current worth
$0.25
Expected worth in 1 year
$-0.03
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.28
Return On Investment
-83.6%

For what price can you sell your share?

Current Price per Share
$0.34
Expected price per share
$0.2542 - $0.43
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Oragenics (5 min.)




Live pricePrice per Share (EOD)
$0.34
Intrinsic Value Per Share
$-7.46 - $7.64
Total Value Per Share
$-7.20 - $7.89

2.2. Growth of Oragenics (5 min.)




Is Oragenics growing?

Current yearPrevious yearGrowGrow %
How rich?$3m$9.9m-$7.3m-290.0%

How much money is Oragenics making?

Current yearPrevious yearGrowGrow %
Making money-$4.9m-$1.4m-$3.5m-71.9%
Net Profit Margin8,463.8%-12,638.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Oragenics (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#722 / 943

Most Revenue
#923 / 943

Most Profit
#429 / 943
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Oragenics?

Welcome investor! Oragenics's management wants to use your money to grow the business. In return you get a share of Oragenics.

First you should know what it really means to hold a share of Oragenics. And how you can make/lose money.

Speculation

The Price per Share of Oragenics is $0.335. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oragenics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oragenics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.25. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oragenics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-60.2%-0.41-122.0%-0.21-63.3%-0.37-110.0%-0.29-85.6%
Usd Book Value Change Per Share0.1442.8%-0.07-20.9%-0.14-41.8%-0.07-21.7%-0.02-5.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.0514.7%0.037.7%
Usd Total Gains Per Share0.1442.8%-0.07-20.9%-0.14-41.8%-0.02-7.0%0.012.5%
Usd Price Per Share0.38-2.12-2.42-1.23-1.04-
Price to Earnings Ratio-0.47--1.25--2.81--1.03--1.21-
Price-to-Total Gains Ratio2.66--15.04--19.55--6.66--5.27-
Price to Book Ratio1.51-9.87-3.58-2.92-3.07-
Price-to-Total Gains Ratio2.66--15.04--19.55--6.66--5.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.335
Number of shares2985
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.05
Usd Book Value Change Per Share-0.07-0.07
Usd Total Gains Per Share-0.07-0.02
Gains per Quarter (2985 shares)-208.96-69.58
Gains per Year (2985 shares)-835.84-278.32
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-836-846589-867-288
20-1672-16821178-1734-566
30-2508-25181767-2602-844
40-3343-33542356-3469-1122
50-4179-41902945-4336-1400
60-5015-50263533-5203-1678
70-5851-58624122-6071-1956
80-6687-66984711-6938-2234
90-7523-75345300-7805-2512
100-8358-83705889-8672-2790

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.086.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.010.01.08.3%4.015.01.020.0%11.028.01.027.5%26.057.03.030.2%
Dividend per Share0.00.04.00.0%1.00.011.08.3%8.00.012.040.0%11.00.029.027.5%11.00.075.012.8%
Total Gains per Share1.03.00.025.0%2.09.01.016.7%5.014.01.025.0%12.027.01.030.0%27.056.03.031.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Oragenics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.143-0.070+149%-0.140+198%-0.073+151%-0.017+112%
Book Value Per Share--0.2520.209+21%0.814-69%1.187-79%0.943-73%
Current Ratio--1.9341.986-3%7.643-75%10.764-82%9.107-79%
Debt To Asset Ratio--0.4090.385+6%0.139+193%0.167+144%0.232+76%
Debt To Equity Ratio--0.6910.662+4%0.163+325%0.236+192%0.661+4%
Dividend Per Share----0%-0%0.049-100%0.026-100%
Enterprise Value--5673024.24026871692.063-79%33921701.120-83%27469998.843-79%22671336.300-75%
Eps---0.202-0.409+103%-0.212+5%-0.369+83%-0.287+42%
Ev To Ebitda Ratio---0.578-1.308+126%-13.090+2164%-3.799+557%-2.876+397%
Ev To Sales Ratio--infinfnan%580.477+inf%infnan%infnan%
Free Cash Flow Per Share---0.161-0.157-3%-0.183+14%-0.262+62%-0.209+30%
Free Cash Flow To Equity Per Share--0.147-0.033+123%-0.174+218%-0.076+151%-0.020+113%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0010%
Intrinsic Value_10Y_max--7.638--------
Intrinsic Value_10Y_min---7.456--------
Intrinsic Value_1Y_max---0.606--------
Intrinsic Value_1Y_min---0.845--------
Intrinsic Value_3Y_max---0.776--------
Intrinsic Value_3Y_min---2.469--------
Intrinsic Value_5Y_max--0.315--------
Intrinsic Value_5Y_min---4.005--------
Market Cap4091254.500-14%4655481.24025913822.813-82%29531529.870-84%15016613.793-69%12709573.700-63%
Net Profit Margin---84.638-100%-126.3810%-38.4770%-20.6360%
Operating Margin---86.259-100%-129.9050%-39.0710%-20.9960%
Operating Ratio----90.0650%131.471-100%38.739-100%20.975-100%
Pb Ratio1.329-14%1.5139.869-85%3.584-58%2.923-48%3.070-51%
Pe Ratio-0.415+12%-0.473-1.248+164%-2.813+495%-1.032+118%-1.212+156%
Price Per Share0.335-14%0.3812.122-82%2.418-84%1.230-69%1.041-63%
Price To Free Cash Flow Ratio-0.519+12%-0.591-4.915+732%-3.552+501%-1.969+233%-1.790+203%
Price To Total Gains Ratio2.336-14%2.658-15.038+666%-19.547+835%-6.659+351%-5.267+298%
Quick Ratio--1.4791.668-11%4.248-65%9.878-85%8.404-82%
Return On Assets---0.473-1.146+142%-0.163-66%-0.438-8%-0.380-20%
Return On Equity---0.800-1.874+134%-0.193-76%-0.617-23%-0.669-16%
Total Gains Per Share--0.143-0.070+149%-0.140+198%-0.023+116%0.008+1612%
Usd Book Value--3077587.0002549350.500+21%9943349.500-69%14493379.050-79%11511624.125-73%
Usd Book Value Change Per Share--0.143-0.070+149%-0.140+198%-0.073+151%-0.017+112%
Usd Book Value Per Share--0.2520.209+21%0.814-69%1.187-79%0.943-73%
Usd Dividend Per Share----0%-0%0.049-100%0.026-100%
Usd Enterprise Value--5673024.24026871692.063-79%33921701.120-83%27469998.843-79%22671336.300-75%
Usd Eps---0.202-0.409+103%-0.212+5%-0.369+83%-0.287+42%
Usd Free Cash Flow---1970250.000-1920393.500-3%-2238047.000+14%-3198540.850+62%-2556066.875+30%
Usd Free Cash Flow Per Share---0.161-0.157-3%-0.183+14%-0.262+62%-0.209+30%
Usd Free Cash Flow To Equity Per Share--0.147-0.033+123%-0.174+218%-0.076+151%-0.020+113%
Usd Market Cap4091254.500-14%4655481.24025913822.813-82%29531529.870-84%15016613.793-69%12709573.700-63%
Usd Price Per Share0.335-14%0.3812.122-82%2.418-84%1.230-69%1.041-63%
Usd Profit---2462870.000-4991555.500+103%-1402758.250-43%-4261654.600+73%-3344892.325+36%
Usd Revenue----9413.2500%70917.750-100%23226.300-100%66191.125-100%
Usd Total Gains Per Share--0.143-0.070+149%-0.140+198%-0.023+116%0.008+1612%
 EOD+2 -6MRQTTM+18 -16YOY+17 -185Y+17 -2010Y+17 -20

3.3 Fundamental Score

Let's check the fundamental score of Oragenics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.415
Price to Book Ratio (EOD)Between0-11.329
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.479
Current Ratio (MRQ)Greater than11.934
Debt to Asset Ratio (MRQ)Less than10.409
Debt to Equity Ratio (MRQ)Less than10.691
Return on Equity (MRQ)Greater than0.15-0.800
Return on Assets (MRQ)Greater than0.05-0.473
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Oragenics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.653
Ma 20Greater thanMa 500.322
Ma 50Greater thanMa 1000.328
Ma 100Greater thanMa 2000.583
OpenGreater thanClose0.370
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Oragenics Inc

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Fundamental data was last updated by Penke on 2024-11-27 08:17:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Oragenics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oragenics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8,463.8%-8,463.8%
TTM8,463.8%YOY-12,638.1%+21,101.9%
TTM8,463.8%5Y-3,847.7%+12,311.4%
5Y-3,847.7%10Y-2,063.6%-1,784.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--107.3%+107.3%
TTM8,463.8%-216.4%+8,680.2%
YOY-12,638.1%-207.4%-12,430.7%
5Y-3,847.7%-349.3%-3,498.4%
10Y-2,063.6%-473.1%-1,590.5%
4.3.1.2. Return on Assets

Shows how efficient Oragenics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • -47.3% Return on Assets means that Oragenics generated $-0.47 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oragenics Inc:

  • The MRQ is -47.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -114.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-47.3%TTM-114.6%+67.3%
TTM-114.6%YOY-16.3%-98.3%
TTM-114.6%5Y-43.8%-70.8%
5Y-43.8%10Y-38.0%-5.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-47.3%-11.6%-35.7%
TTM-114.6%-11.9%-102.7%
YOY-16.3%-11.2%-5.1%
5Y-43.8%-12.6%-31.2%
10Y-38.0%-14.2%-23.8%
4.3.1.3. Return on Equity

Shows how efficient Oragenics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • -80.0% Return on Equity means Oragenics generated $-0.80 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oragenics Inc:

  • The MRQ is -80.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -187.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.0%TTM-187.4%+107.4%
TTM-187.4%YOY-19.3%-168.1%
TTM-187.4%5Y-61.7%-125.7%
5Y-61.7%10Y-66.9%+5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.0%-14.4%-65.6%
TTM-187.4%-16.1%-171.3%
YOY-19.3%-14.6%-4.7%
5Y-61.7%-18.6%-43.1%
10Y-66.9%-19.2%-47.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Oragenics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Oragenics is operating .

  • Measures how much profit Oragenics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oragenics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8,625.9%-8,625.9%
TTM8,625.9%YOY-12,990.5%+21,616.4%
TTM8,625.9%5Y-3,907.1%+12,533.0%
5Y-3,907.1%10Y-2,099.6%-1,807.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM8,625.9%-316.3%+8,942.2%
YOY-12,990.5%-215.6%-12,774.9%
5Y-3,907.1%-377.4%-3,529.7%
10Y-2,099.6%-480.8%-1,618.8%
4.3.2.2. Operating Ratio

Measures how efficient Oragenics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Oragenics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-90.065+90.065
TTM-90.065YOY131.471-221.535
TTM-90.0655Y38.739-128.804
5Y38.73910Y20.975+17.764
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.270-2.270
TTM-90.0653.220-93.285
YOY131.4713.231+128.240
5Y38.7394.696+34.043
10Y20.9756.430+14.545
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Oragenics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Oragenics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.93 means the company has $1.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Oragenics Inc:

  • The MRQ is 1.934. The company is able to pay all its short-term debts. +1
  • The TTM is 1.986. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.934TTM1.986-0.051
TTM1.986YOY7.643-5.657
TTM1.9865Y10.764-8.779
5Y10.76410Y9.107+1.657
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9343.586-1.652
TTM1.9863.865-1.879
YOY7.6434.644+2.999
5Y10.7645.954+4.810
10Y9.1076.215+2.892
4.4.3.2. Quick Ratio

Measures if Oragenics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • A Quick Ratio of 1.48 means the company can pay off $1.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oragenics Inc:

  • The MRQ is 1.479. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.668. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.479TTM1.668-0.189
TTM1.668YOY4.248-2.580
TTM1.6685Y9.878-8.210
5Y9.87810Y8.404+1.474
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4793.090-1.611
TTM1.6683.388-1.720
YOY4.2484.302-0.054
5Y9.8785.952+3.926
10Y8.4046.434+1.970
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Oragenics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Oragenics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oragenics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Oragenics assets are financed with 40.9% credit (debt) and the remaining percentage (100% - 40.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oragenics Inc:

  • The MRQ is 0.409. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.385. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.409TTM0.385+0.024
TTM0.385YOY0.139+0.245
TTM0.3855Y0.167+0.217
5Y0.16710Y0.232-0.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4090.347+0.062
TTM0.3850.347+0.038
YOY0.1390.314-0.175
5Y0.1670.365-0.198
10Y0.2320.383-0.151
4.5.4.2. Debt to Equity Ratio

Measures if Oragenics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oragenics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 69.1% means that company has $0.69 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oragenics Inc:

  • The MRQ is 0.691. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.662. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.691TTM0.662+0.029
TTM0.662YOY0.163+0.499
TTM0.6625Y0.236+0.426
5Y0.23610Y0.661-0.425
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6910.393+0.298
TTM0.6620.432+0.230
YOY0.1630.390-0.227
5Y0.2360.456-0.220
10Y0.6610.498+0.163
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Oragenics generates.

  • Above 15 is considered overpriced but always compare Oragenics to the Biotechnology industry mean.
  • A PE ratio of -0.47 means the investor is paying $-0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oragenics Inc:

  • The EOD is -0.415. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.473. Based on the earnings, the company is expensive. -2
  • The TTM is -1.248. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.415MRQ-0.473+0.057
MRQ-0.473TTM-1.248+0.775
TTM-1.248YOY-2.813+1.565
TTM-1.2485Y-1.032-0.216
5Y-1.03210Y-1.212+0.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.415-2.114+1.699
MRQ-0.473-2.510+2.037
TTM-1.248-3.161+1.913
YOY-2.813-3.257+0.444
5Y-1.032-6.006+4.974
10Y-1.212-6.717+5.505
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oragenics Inc:

  • The EOD is -0.519. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.591. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.915. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.519MRQ-0.591+0.072
MRQ-0.591TTM-4.915+4.325
TTM-4.915YOY-3.552-1.364
TTM-4.9155Y-1.969-2.947
5Y-1.96910Y-1.790-0.178
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.519-2.918+2.399
MRQ-0.591-3.283+2.692
TTM-4.915-3.669-1.246
YOY-3.552-4.504+0.952
5Y-1.969-8.046+6.077
10Y-1.790-9.219+7.429
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Oragenics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.51 means the investor is paying $1.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Oragenics Inc:

  • The EOD is 1.329. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.513. Based on the equity, the company is underpriced. +1
  • The TTM is 9.869. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD1.329MRQ1.513-0.183
MRQ1.513TTM9.869-8.356
TTM9.869YOY3.584+6.285
TTM9.8695Y2.923+6.946
5Y2.92310Y3.070-0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3291.956-0.627
MRQ1.5132.067-0.554
TTM9.8692.387+7.482
YOY3.5842.465+1.119
5Y2.9233.704-0.781
10Y3.0704.350-1.280
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Oragenics Inc.

4.8.3. Insider Transactions

Insiders are holding 25.409% of the shares of Oragenics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-06-17Telling FredBUY100840.291010000
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Depreciation and Amortization  53944-37707-22-16
Total Other Income Expense Net 45449-409-81-27-26



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. All numbers in thousands.

Summary
Total Assets5,204
Total Liabilities2,127
Total Stockholder Equity3,078
 As reported
Total Liabilities 2,127
Total Stockholder Equity+ 3,078
Total Assets = 5,204

Assets

Total Assets5,204
Total Current Assets4,113
Long-term Assets1,091
Total Current Assets
Cash And Cash Equivalents 3,144
Other Current Assets 969
Total Current Assets  (as reported)4,113
Total Current Assets  (calculated)4,113
+/-0
Long-term Assets
Long-term Assets Other 1,091
Long-term Assets  (as reported)1,091
Long-term Assets  (calculated)1,091
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,127
Long-term Liabilities1,607
Total Stockholder Equity3,078
Total Current Liabilities
Short-term Debt 519
Short Long Term Debt 519
Accounts payable 1,513
Other Current Liabilities 94
Total Current Liabilities  (as reported)2,127
Total Current Liabilities  (calculated)2,646
+/- 519
Long-term Liabilities
Long-term Liabilities  (as reported)1,607
Long-term Liabilities  (calculated)0
+/- 1,607
Total Stockholder Equity
Common Stock9
Retained Earnings -213,437
Other Stockholders Equity 214,913
Total Stockholder Equity (as reported)3,078
Total Stockholder Equity (calculated)1,485
+/- 1,593
Other
Capital Stock1,602
Cash and Short Term Investments 3,144
Common Stock Shares Outstanding 6,528
Liabilities and Stockholders Equity 5,204
Net Debt -2,625
Net Invested Capital 2,004
Net Working Capital 1,987
Short Long Term Debt Total 519



5.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-31
> Total Assets 
0
1,939
1,821
3,651
6,101
5,369
4,808
4,466
3,794
3,096
2,156
2,146
1,906
1,969
1,470
1,606
1,593
1,069
1,735
1,151
2,553
4,264
3,267
1,594
1,594
2,127
1,080
3,203
2,228
1,678
2,641
1,728
1,178
1,307
1,229
1,267
1,267
1,983
12,584
10,488
8,823
7,071
8,815
16,831
15,141
13,337
12,303
11,132
9,761
8,695
7,390
5,778
3,957
6,137
5,396
4,309
2,351
4,577
5,135
7,215
5,494
5,209
15,536
22,050
31,309
26,933
23,652
19,753
15,562
10,732
11,282
18,681
37,366
35,248
31,091
28,231
22,204
18,465
15,041
14,758
14,758
8,464
7,899
4,966
3,534
2,710
5,204
5,2042,7103,5344,9667,8998,46414,75814,75815,04118,46522,20428,23131,09135,24837,36618,68111,28210,73215,56219,75323,65226,93331,30922,05015,5365,2095,4947,2155,1354,5772,3514,3095,3966,1373,9575,7787,3908,6959,76111,13212,30313,33715,14116,8318,8157,0718,82310,48812,5841,9831,2671,2671,2291,3071,1781,7282,6411,6782,2283,2031,0802,1271,5941,5943,2674,2642,5531,1511,7351,0691,5931,6061,4701,9691,9062,1462,1563,0963,7944,4664,8085,3696,1013,6511,8211,9390
   > Total Current Assets 
0
1,913
1,784
3,608
6,039
5,294
4,502
3,775
2,590
1,861
987
1,050
882
1,015
585
781
831
376
1,107
592
2,094
3,850
2,884
1,271
1,271
1,952
963
3,127
2,165
1,619
2,413
1,499
970
1,119
1,061
1,118
1,118
1,871
12,491
10,404
8,759
7,023
8,777
16,805
15,102
13,305
12,277
11,023
9,594
8,525
7,231
5,638
3,835
6,033
5,288
4,222
2,281
4,526
5,101
7,193
5,480
5,198
15,472
21,933
31,073
26,075
22,847
18,838
14,701
9,925
10,529
17,983
36,724
34,662
30,535
27,707
21,650
17,970
14,513
14,290
14,290
8,099
7,814
3,866
2,443
1,619
4,113
4,1131,6192,4433,8667,8148,09914,29014,29014,51317,97021,65027,70730,53534,66236,72417,98310,5299,92514,70118,83822,84726,07531,07321,93315,4725,1985,4807,1935,1014,5262,2814,2225,2886,0333,8355,6387,2318,5259,59411,02312,27713,30515,10216,8058,7777,0238,75910,40412,4911,8711,1181,1181,0611,1199701,4992,4131,6192,1653,1279631,9521,2711,2712,8843,8502,0945921,1073768317815851,0158821,0509871,8612,5903,7754,5025,2946,0393,6081,7841,9130
       Cash And Cash Equivalents 
0
1,868
1,693
3,584
6,012
5,146
4,314
3,666
2,381
1,682
852
938
726
862
470
707
750
151
936
476
1,967
3,634
2,700
1,166
1,166
1,820
725
302
459
217
505
132
56
441
383
172
172
1,130
11,758
9,926
8,350
6,368
8,268
16,277
14,639
12,899
11,765
10,449
9,053
8,044
6,739
5,083
3,368
5,457
5,117
4,081
2,175
2,089
2,923
6,166
4,758
3,941
13,811
20,208
29,349
25,720
22,292
18,268
14,372
9,629
10,044
17,640
36,501
34,575
29,949
27,266
21,372
17,867
13,951
11,427
11,427
6,474
5,767
3,484
2,072
1,349
3,144
3,1441,3492,0723,4845,7676,47411,42711,42713,95117,86721,37227,26629,94934,57536,50117,64010,0449,62914,37218,26822,29225,72029,34920,20813,8113,9414,7586,1662,9232,0892,1754,0815,1175,4573,3685,0836,7398,0449,05310,44911,76512,89914,63916,2778,2686,3688,3509,92611,7581,130172172383441561325052174593027251,8201,1661,1662,7003,6341,9674769361517507074708627269388521,6822,3813,6664,3145,1466,0123,5841,6931,8680
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,450
896
742
555
476
389
441
383
265
294
195
144
62
26
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,919
1,408
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
0
0
0
0
0
000000180000000000000000000001,4081,919000000000000000026621441952942653834413894765557428962,450000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
20
10
163
222
174
212
485
96
55
44
93
93
39
72
70
55
50
59
64
43
23
26
16
30
27
19
21
33
450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
0
0
13
35
0
0
0
0
0000351300777700000000000000000000045033211927301626234364595055707239939344559648521217422216310206600000000000000000000000
       Other Current Assets 
0
45
91
25
27
148
187
109
209
179
135
112
156
154
0
74
81
225
171
117
127
216
184
88
87
70
114
2,531
1,206
813
459
616
543
563
551
113
378
348
381
284
236
302
227
175
154
145
222
119
134
90
173
212
193
125
172
141
106
2,437
2,178
1,027
723
1,257
1,661
1,725
1,724
355
555
570
329
295
486
343
223
87
587
435
277
102
562
2,863
2,863
1,612
2,012
382
371
270
969
9692703713822,0121,6122,8632,863562102277435587872233434862953295705553551,7241,7251,6611,2577231,0272,1782,437106141172125193212173901341192221451541752273022362843813483781135515635436164598131,2062,53111470878818421612711717122581740154156112135179209109187148272591450
   > Long-term Assets 
0
25
37
42
61
75
307
691
1,204
1,235
1,169
1,097
1,024
954
886
825
762
693
628
559
459
414
383
0
323
175
117
75
63
59
227
228
208
188
168
149
149
111
93
85
64
49
38
27
39
32
26
109
168
171
159
141
122
104
107
87
69
52
34
22
14
11
64
116
236
858
805
915
861
807
753
698
642
586
556
524
554
495
528
469
469
366
85
1,101
1,091
1,091
1,091
1,0911,0911,0911,10185366469469528495554524556586642698753807861915805858236116641114223452698710710412214115917116810926323927384964859311114914916818820822822759637511717532303834144595596286937628258869541,0241,0971,1691,2351,20469130775614237250
       Property Plant Equipment 
0
25
37
42
61
75
307
691
1,204
1,235
1,169
1,097
1,024
954
886
825
762
693
628
559
459
414
383
323
323
175
117
75
63
59
227
228
208
188
168
149
149
111
93
85
64
49
38
27
39
32
26
109
168
171
159
141
122
104
107
87
69
52
34
22
14
11
64
116
236
858
805
915
861
807
753
698
642
586
556
524
554
495
528
469
469
348
77
10
0
0
0
000107734846946952849555452455658664269875380786191580585823611664111422345269871071041221411591711681092632392738496485931111491491681882082282275963751171753233233834144595596286937628258869541,0241,0971,1691,2351,20469130775614237250
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
655
0
0
0
0
0
0
0
0
0
18
9
0
0
0
0
000091800000000065500000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
334
236
211
210
212
327
430
834
812
765
375
368
400
325
328
362
375
248
331
398
365
474
1,771
1,771
3,415
1,973
563
642
1,760
2,465
3,627
4,518
6,293
7,810
9,446
9,446
3,432
1,753
1,256
1,174
1,388
4,453
993
938
778
740
796
606
5,601
5,887
1,047
1,083
898
909
1,343
1,165
4,072
4,122
899
1,179
1,558
1,557
1,168
2,185
2,510
2,833
2,521
2,653
1,944
1,642
1,836
1,315
2,514
2,545
1,745
1,663
1,678
1,703
1,749
1,749
1,207
1,402
1,798
909
1,383
2,127
2,1271,3839091,7981,4021,2071,7491,7491,7031,6781,6631,7452,5452,5141,3151,8361,6421,9442,6532,5212,8332,5102,1851,1681,5571,5581,1798994,1224,0721,1651,3439098981,0831,0475,8875,6016067967407789389934,4531,3881,1741,2561,7533,4329,4469,4467,8106,2934,5183,6272,4651,7606425631,9733,4151,7711,7714743653983312483753623283254003683757658128344303272122102112363340
   > Total Current Liabilities 
0
334
236
211
210
212
327
430
470
438
765
375
368
400
325
328
362
375
248
331
398
365
474
1,771
1,771
2,415
973
563
642
1,760
2,465
1,627
1,518
1,793
7,810
9,446
9,446
1,376
1,753
1,256
1,174
1,388
4,453
993
938
778
740
796
606
5,601
5,887
1,047
1,083
898
909
1,343
1,165
1,084
1,722
899
1,179
1,558
1,557
1,168
2,185
1,894
2,247
1,850
2,025
1,360
1,102
1,342
869
2,116
2,196
1,445
1,409
1,460
1,498
1,596
1,596
1,141
1,402
1,798
909
1,383
2,127
2,1271,3839091,7981,4021,1411,5961,5961,4981,4601,4091,4452,1962,1168691,3421,1021,3602,0251,8502,2471,8942,1851,1681,5571,5581,1798991,7221,0841,1651,3439098981,0831,0475,8875,6016067967407789389934,4531,3881,1741,2561,7531,3769,4469,4467,8101,7931,5181,6272,4651,7606425639732,4151,7711,7714743653983312483753623283254003683757654384704303272122102112363340
       Short-term Debt 
0
85
85
0
0
0
0
0
193
194
521
0
0
0
0
0
0
0
0
0
0
69
53
28
28
132
72
35
60
1,030
159
99
109
66
6,104
7,553
7,553
35
88
48
67
142
108
64
80
36
110
65
79
35
5,110
63
79
35
112
66
63
23
128
80
68
21
190
124
210
153
353
309
239
303
646
405
296
186
672
498
315
181
627
0
472
190
518
332
127
0
519
519012733251819047206271813154986721862964056463032393093531532101241902168801282363661123579635,110357965110368064108142674888357,5537,5536,10466109991591,0306035721322828536900000000005211941930000085850
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
0
0
0
63
0
0
0
66
63
2,423
2,528
80
68
21
0
0
78
13
217
144
71
132
472
228
115
0
482
303
122
0
425
268
108
0
493
0
127
0
519
51901270493010826842501223034820115228472132711442171378002168802,5282,4236366000630006500000000000000000000000000000000000000000000000
       Accounts payable 
0
181
83
141
210
212
327
430
278
244
243
375
253
235
176
328
253
288
161
331
338
253
378
494
2,583
2,283
791
194
573
679
1,291
746
1,311
1,611
1,544
1,740
631
1,255
1,399
440
1,082
1,222
2,365
249
491
696
602
484
506
549
511
384
579
536
589
461
796
446
699
618
1,049
1,537
1,367
829
1,975
1,694
1,839
1,207
1,787
1,057
457
330
573
1,930
1,523
855
1,094
1,280
871
247
247
591
809
1,245
696
1,180
1,513
1,5131,1806961,2458095912472478711,2801,0948551,5231,9305733304571,0571,7871,2071,8391,6941,9758291,3671,5371,0496186994467964615895365793845115495064846026964912492,3651,2221,0824401,3991,2556311,7401,5441,6111,3117461,2916795731947912,2832,583494378253338331161288253328176235253375243244278430327212210141831810
       Other Current Liabilities 
0
46
45
70
0
0
0
0
0
0
0
0
116
165
150
0
110
87
87
0
60
43
43
1,249
1,744
2,283
791
284
573
679
1,000
1,515
1,312
1,611
1,544
153
1,083
1,255
1,399
692
1,082
1,222
1,956
661
316
8
3
227
3
5,000
250
586
408
327
209
816
306
615
895
200
62
1,537
1,367
215
132
47
56
499
1,787
1,057
457
784
573
1,930
1,523
93
1,094
1,280
948
0
878
951
884
221
86
203
94
942038622188495187809481,2801,094931,5231,9305737844571,0571,78749956471322151,3671,537622008956153068162093274085862505,0003227383166611,9561,2221,0826921,3991,2551,0831531,5441,6111,3121,5151,0006795732847912,2831,7441,249434360087871100150165116000000007045460
   > Long-term Liabilities 
0
267
168
141
210
212
327
430
364
374
765
375
253
235
176
328
253
288
161
331
338
323
431
0
28
1,000
1,000
279
68
1,081
174
2,000
3,000
4,500
6,266
0
8,363
2,056
354
565
91
165
2,497
332
131
75
135
570
97
601
5,125
461
96
35
112
528
63
2,988
2,400
699
68
1,558
1,557
953
2,053
616
586
671
628
584
539
494
446
398
349
300
254
217
205
152
152
66
0
0
782
0
1,607
1,607078200661521522052172543003493984464945395846286715866162,0539531,5571,558686992,4002,9886352811235964615,12560197570135751313322,497165915653542,0568,36306,2664,5003,0002,0001741,081682791,0001,0002804313233383311612882533281762352533757653743644303272122101411682670
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
0
0
774
2,056
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000002,056774004,500000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
588
2,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000002,400588000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
588
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000588000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
1,604
1,584
3,440
5,891
5,158
4,481
4,036
2,960
2,283
1,391
1,772
1,538
1,569
1,145
1,278
1,230
695
1,487
820
2,155
3,899
2,793
0
-177
-1,288
-893
2,640
1,587
-82
176
-1,899
-3,339
-4,985
-6,581
-8,179
-8,179
-1,449
10,831
9,232
7,649
5,683
4,362
15,839
14,203
12,559
11,564
10,336
9,156
3,094
1,503
4,731
2,874
5,239
4,486
2,966
1,186
505
1,013
6,316
4,315
3,651
13,979
20,882
29,124
24,423
20,819
17,232
12,909
8,788
9,640
16,845
36,050
32,733
28,546
26,486
20,541
16,787
13,338
13,009
13,009
7,257
6,497
3,168
2,625
1,326
3,078
3,0781,3262,6253,1686,4977,25713,00913,00913,33816,78720,54126,48628,54632,73336,05016,8459,6408,78812,90917,23220,81924,42329,12420,88213,9793,6514,3156,3161,0135051,1862,9664,4865,2392,8744,7311,5033,0949,15610,33611,56412,55914,20315,8394,3625,6837,6499,23210,831-1,449-8,179-8,179-6,581-4,985-3,339-1,899176-821,5872,640-893-1,288-17702,7933,8992,1558201,4876951,2301,2781,1451,5691,5381,7721,3912,2832,9604,0364,4815,1585,8913,4401,5841,6040
   Common Stock
0
12
12
13
14
14
14
15
15
15
15
18
20
21
21
22
23
23
28
28
33
38
38
38
38
90
91
106
108
108
6
6
6
6
6
6
6
17
27
27
27
28
30
36
36
36
36
36
36
36
36
40
40
49
49
49
49
49
49
5
5
6
18
29
46
46
46
46
46
55
61
92
116
116
116
116
116
116
117
2
2
2
3
3
4
6
9
964332221171161161161161161169261554646464646291865549494949494940403636363636363636302827272717666666610810810691903838383833282823232221212018151515151414141312120
   Retained Earnings Total Equity0000000000000-164,598-160,782-154,445-150,036-145,539-133,202-127,353-123,756-119,919-115,113-111,374-108,618-105,860-103,579-101,401-99,940-97,873-96,652-94,669-91,994-90,031-89,719-87,656-85,437-83,573-77,237-75,945-74,721-73,692-71,796-70,155-67,076-57,750-55,676-54,086-52,098-49,542-42,613-40,996-39,057-37,249000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0-1,593-1,593-3-1,593-1,593000000000000-1,664-1,664000-1,615000-1,584000-1,519-1,015-2,000-1,448-1,448000-1,557000-1,53000-1,453-1,45300-1,378-1,37800-1,299-1,29900-1,257-1,25700-1,074-1,074-870-870-870-870-596-596-596-596-316-316-316-316-59-59-59-59-17-17-17-17000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,258
32,470
32,811
42,286
48,076
62,901
63,291
63,298
63,406
71,408
85,958
85,963
86,214
86,248
86,245
86,357
86,631
86,903
92,347
92,553
97,222
97,447
97,616
97,788
97,847
99,658
101,403
101,789
103,404
115,765
126,126
137,677
137,782
138,015
138,025
138,890
147,097
152,440
164,023
194,061
194,558
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000194,558194,061164,023152,440147,097138,890138,025138,015137,782137,677126,126115,765103,404101,789101,40399,65897,84797,78897,61697,44797,22292,55392,34786,90386,63186,35786,24586,24886,21485,96385,95871,40863,40663,29863,29162,90148,07642,28632,81132,47032,258000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
2,962
3,339
5,837
8,825
8,759
8,697
9,552
9,342
9,538
9,397
10,793
11,414
12,241
12,376
13,511
14,004
14,064
15,339
15,632
17,755
20,588
20,620
0
20,851
21,464
23,295
29,302
28,738
29,079
31,314
32,711
31,531
32,258
32,470
0
34,189
48,076
62,901
64,744
63,298
63,406
71,408
87,487
85,963
86,214
86,248
87,802
86,357
86,631
86,903
93,795
92,553
97,222
97,447
99,105
97,788
97,847
99,658
102,987
101,789
103,404
115,765
127,741
137,677
137,782
138,015
139,689
138,890
147,097
152,440
164,023
194,061
194,558
194,755
194,987
195,077
195,356
196,888
0
196,977
198,713
199,966
207,791
209,697
210,702
214,913
214,913210,702209,697207,791199,966198,713196,9770196,888195,356195,077194,987194,755194,558194,061164,023152,440147,097138,890139,689138,015137,782137,677127,741115,765103,404101,789102,98799,65897,84797,78899,10597,44797,22292,55393,79586,90386,63186,35787,80286,24886,21485,96387,48771,40863,40663,29864,74462,90148,07634,189032,47032,25831,53132,71131,31429,07928,73829,30223,29521,46420,851020,62020,58817,75515,63215,33914,06414,00413,51112,37612,24111,41410,7939,3979,5389,3429,5528,6978,7598,8255,8373,3392,9620



5.4. Balance Sheets

All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue38
Cost of Revenue-15,491
Gross Profit-15,453-15,453
 
Operating Income (+$)
Gross Profit-15,453
Operating Expense-5,452
Operating Income-20,905-20,905
 
Operating Expense (+$)
Research Development15,491
Selling General Administrative5,452
Selling And Marketing Expenses0
Operating Expense5,45220,943
 
Net Interest Income (+$)
Interest Income239
Interest Expense-31
Other Finance Cost-6
Net Interest Income215
 
Pretax Income (+$)
Operating Income-20,905
Net Interest Income215
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,656-21,154
EBIT - interestExpense = -20,935
-20,656
-20,625
Interest Expense31
Earnings Before Interest and Taxes (EBIT)-20,905-20,625
Earnings Before Interest and Taxes (EBITDA)-20,878
 
After tax Income (+$)
Income Before Tax-20,656
Tax Provision-0
Net Income From Continuing Ops-10,146-20,656
Net Income-20,656
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses20,943
Total Other Income/Expenses Net249-215
 

Technical Analysis of Oragenics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oragenics. The general trend of Oragenics is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oragenics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oragenics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.385 < 0.41 < 0.43.

The bearish price targets are: 0.2542.

Tweet this
Oragenics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oragenics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oragenics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oragenics Inc. The current macd is 0.00188639.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Oragenics price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Oragenics. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Oragenics price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Oragenics Inc Daily Moving Average Convergence/Divergence (MACD) ChartOragenics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oragenics Inc. The current adx is 13.84.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Oragenics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Oragenics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oragenics Inc. The current sar is 0.28838189.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Oragenics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oragenics Inc. The current rsi is 49.65. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Oragenics Inc Daily Relative Strength Index (RSI) ChartOragenics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oragenics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -3/(-6 +6).

  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oragenics price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Oragenics Inc Daily Stochastic Oscillator ChartOragenics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oragenics Inc. The current cci is 68.89.

Oragenics Inc Daily Commodity Channel Index (CCI) ChartOragenics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oragenics Inc. The current cmo is 0.24206244.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Oragenics Inc Daily Chande Momentum Oscillator (CMO) ChartOragenics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oragenics Inc. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Oragenics is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Oragenics Inc Daily Williams %R ChartOragenics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oragenics Inc.

Oragenics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oragenics Inc. The current atr is 0.03562563.

Oragenics Inc Daily Average True Range (ATR) ChartOragenics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oragenics Inc. The current obv is 7,661,320.

Oragenics Inc Daily On-Balance Volume (OBV) ChartOragenics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oragenics Inc. The current mfi is 78.77.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Oragenics Inc Daily Money Flow Index (MFI) ChartOragenics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oragenics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Oragenics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oragenics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.653
Ma 20Greater thanMa 500.322
Ma 50Greater thanMa 1000.328
Ma 100Greater thanMa 2000.583
OpenGreater thanClose0.370
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Oragenics with someone you think should read this too:
  • Are you bullish or bearish on Oragenics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oragenics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oragenics Inc

I send you an email if I find something interesting about Oragenics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Oragenics Inc.

Receive notifications about Oragenics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.